New blood-cleaning device offers hope for iron overload in rare blood cancers
NCT ID NCT06781099
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 35 times
Summary
This study tests a new device that filters excess iron from the blood in people with myelodysplastic syndrome (MDS) or myelofibrosis who cannot take standard iron-removing medications. Participants will undergo three short dialysis-like sessions over one week. The goal is to see if the device is safe, tolerable, and effective at reducing iron levels, which may help prevent organ damage from repeated blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Lyon Sud
RECRUITINGOullins-Pierre-Bénite, 69495, France
-
Hôpital Lyon Sud
RECRUITINGOullins-Pierre-Bénite, 69495, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.